Description

FTISADTSK acetate is an endogenous stable signature peptide from Trastuzumab monitored by selected reaction monitoring (SRM)[1].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–Cancer-programmed cell death–C44H72N10O18—-[1]Bults P, et al. LC-MS/MS-Based Monitoring of In Vivo Protein Biotransformation: Quantitative Determination of Trastuzumab and Its Deamidation Products in Human Plasma. Anal Chem. 2016;88(3):1871-1877.—-1029.10–99.66–O=C(N[C@@H](CO)C(N[C@@H](C)C(N[C@@H](CC(O)=O)C(N[C@@H]([C@H](O)C)C(N[C@@H](CO)C(N[C@H](C(O)=O)CCCCN)=O)=O)=O)=O)=O)[C@H]([C@@H](C)CC)NC([C@H]([C@H](O)C)NC([C@@H](N)CC1=CC=CC=C1)=O)=O.CC(O)=O–Cancer–H2O : 50 mg/mL (ultrasonic)–Drug Metabolite—-Metabolic Enzyme/Protease–Peptides